Status:
UNKNOWN
Potential Role of Gum Arabic as Immunomodulatory Agent Among COVID 19 Patients
Lead Sponsor:
Al-Neelain University
Collaborating Sponsors:
University of Khartoum
Conditions:
COVID 19
Eligibility:
All Genders
5-90 years
Phase:
PHASE2
PHASE3
Brief Summary
To study the efficacy of Gum Arabic as an immuno modulator and anti-inflammatory agent among COVID 19 seropositive patients..Half of participants will receive Gum Arabic and the other half will receiv...
Detailed Description
Randomized placebo controlled trial including COVID 19 seropositive patients will be treated with 30 gram per day for 4 weeks, compared to placebo group treated for the same duration in positive COVID...
Eligibility Criteria
Inclusion
- COVID 19 infected as proved by real time PCR (polymerase chain reaction) .( newly diagnosed)
Exclusion
- Intubated patients on parental treatment
Key Trial Info
Start Date :
June 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2020
Estimated Enrollment :
110 Patients enrolled
Trial Details
Trial ID
NCT04381871
Start Date
June 1 2020
End Date
September 1 2020
Last Update
May 12 2020
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Omdurman Teaching Hospital
Khartoum, Omdurman, Sudan
2
Jabra Hospital,
Khartoum, Sudan